Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
Pyoderma gangrenosum (PG) is an inflammatory ulcerative condition of unknown etiology. An autoimmune mechanism including immune complex-mediated neutrophilic vascular reactions has been suggested. The role of tumor necrosis factor (TNF) in PG remains unclear. Evidence supports the idea that TNF play...
| Publicado en: | International Journal of Lower Extremity Wounds Vol. 6; no. 2; pp. 108 - 114 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Sage Publications Inc.
Jun2007
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105931397&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105931397 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15347346 IYG jtl: International Journal of Lower Extremity Wounds issn: 15347346 maglogo: Y pubinfo: dt: Jun2007 vid: 6 iid: 2 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 105931397 2009594736 10.1177/1534734607300912 NLM17558009 105931397 ppf: 108 ppct: 6 formats: tig: atl: Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. aug: au: Dini V Romanelli M Bertone M Talarico S Bombardieri S Barachini P affil: Wound Healing Research Unit, Department of Dermatology sug: subj: Infliximab Administration and Dosage Leg Ulcer Therapy Pyoderma Gangrenosum Drug Therapy Tumor Necrosis Factor Aged Female Infliximab Adverse Effects Middle Age Pyoderma Gangrenosum Risk Factors Aged: 65+ years Middle Aged: 45-64 years Female ab: Pyoderma gangrenosum (PG) is an inflammatory ulcerative condition of unknown etiology. An autoimmune mechanism including immune complex-mediated neutrophilic vascular reactions has been suggested. The role of tumor necrosis factor (TNF) in PG remains unclear. Evidence supports the idea that TNF plays a role in chronic inflammation and migration of neutrophils to these lesions. PG is frequently associated with various diseases, but up to 50% of cases are idiopathic. There are several reports describing the successful use of infliximab (Remicade, Centocor, Inc, Horsham, Pa), a chimeric antitumor necrosis factor alpha monoclonal antibody, in the treatment of inflammatory bowel disease- associated PG, but there have been few reported cases of infliximab in the treatment of idiopathic PG. The authors present a dramatic improvement in 4 cases of idiopathic PG of the lower leg treated with infliximab. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|